News
-
Oragenics announced that it has raised approximately $16.5 million in a Series H funding round, with proceeds going toward repayment of a $3 million bridge loan and continued development of the company’s OPN-002 neurosteroid nasal… Read more . . .
-
German startup Ebenbuild has received a €2.3 million grant plus a commitment for up to an additional €10 million in future investments from the European Innovation Council (EIC) Accelerator program, the company said. The funding… Read more . . .
-
Beckley Psytech and atai Life Sciences have announced that a Phase 2b trial of Beckley’s BPL-003 intranasal mebufotenin (5-MeO-DMT) in patients with treatment-resistant depression met its primary endpoint, demonstrating a significant reduction in symptoms of depression… Read more . . .
-
Intranasal drug developer Vistagen has announced the appointment of Elissa Cote as Chief Corporate Development Officer. According to her LinkedIn page, Cote served as a strategic advisor to Narcan nasal spray developer Emergent Biosolutions from January 2023 to… Read more . . .
-
According to Theravance Biopharma, a marketing application submitted to the Chinese National Medical Products Administration (NMPA) by Viatris for Yupelri revefenacin inhalation solution for the treatment of COPD has been approved. In November 2023, Theravance and Viatris announced… Read more . . .
-
Bryn Pharma announced that it has initiated a PK/PD trial of its epinephrine spray in an updated delivery device, with topline data expected in the third quarter of this year. The company said that the… Read more . . .
-
GH Research announced that it has submitted its response to a clinical hold of an IND for the company’s GH001 inhaled mebufotenin (5-MeO-DMT) for the treatment of treatment-resistant depression. The FDA cited “Insufficient information to… Read more . . .
-
CDMO Kindeva has announced an agreement with Canadian company Rocket Science Health (RSH) for development of RSH’s “Olfactory Delivery Device,” which is designed for high deposition of drug to the olfactory clefts. Kindeva, which acquired nasal… Read more . . .
-
Lupin announced that it has signed an agreement with Sino Universal Pharmaceuticals for commercialization of Lupin’s tiotropium dry powder inhaler in China for the treatment of COPD. Per the agreement, Sino Universal will obtain marketing… Read more . . .
-
Milestone Pharmaceuticals says that it completed a Type A meeting with the FDA and subsequently submitted its response to the agency’s complete response letter regarding Milestone’s NDA for Cardamyst etripamil nasal spray for the treatment of… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland